Our Commitment in the Fight Against COVID-19 3898

Our Commitment in the Fight Against COVID-19

Our Response to COVID-19

Supporting Our Employees

Our focus remains first and foremost the health and well-being of our employees who are keeping the delivery of your needs front and center during this unprecedented time. By moving to two shifts we have facilitated employees’ social distancing at work while providing all required PPE and other safety measures, to assure the well-being of our employees and their families. We continue to be very fortunate in that none of our employees have been tested positive for COVID-19.

Supporting Our Community

Personal protective equipment (PPE) is in high demand, especially among frontline health care workers, who are putting their safety at risk every day in order to help others. Frontage Laboratories has been fortunate to be able to assist our local heroes by donating PPE to 11 hospitals in the vicinity of our sites in Pennsylvania, New Jersey and Ohio. In total, Frontage is on target to complete the donation of over 100,000 surgical masks, 50,000 face shields, 5,000 N95 masks, 4,000 goggles, and 6,500 coveralls. Frontage continues to build sustainable community partnerships with our local hospitals during this time of need and appreciate all the dedication from the doctors, nurses and health care workers, as they navigate the fluid landscape of COVID-19.

Supporting Our Clients

  • Our bioanalytical and biologics teams are supporting the development of an assay kit designed to detect COVID-19 virus and antibodies and provide results within 15 minutes.
  • We are doing the bioanalysis in support of a client’s late stage clinical program directed to a COVID-19 treatment.
  • We are developing and validating a 3-in-1 LC-MS/MS method for the determination of Chloroquine, hydroxychloroquine, and azithromycin in human plasma. Those drugs are under evaluation as a treatment of COVID-19.
  • We are providing PK and PD biomarkers testing to a number of pharma companies and universities in supporting their COVID-19 related clinical trials.